我如何治疗遗传性出血端膜切除症中的出血
1Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Blood
|June 12, 2024
概括
遗传性出血端膜炎 (HHT) 是一种常见的遗传性出血障碍. 新的全身疗法,包括抗纤维解药和抗血管生成药,为HTT相关的出血和贫血提供了有效的治疗选择.
科学领域:
- 血管医学 血管医学
- 血液学 血液学 血液学
背景情况:
- 遗传性出血端膜炎 (HHT),也称为奥斯勒-韦伯-伦杜病,影响5000个个体中的1个,使其成为一种重要的遗传性出血障碍.
- 主要表现包括反复出现的表和慢性胃肠道出血,导致心理疾病和严重的缺铁性贫血.
研究的目的:
- 提供关于现代,基于证据的HHT出血管理的指导.
- 用病例来说明常见和具有挑战性的HTH出血表现.
- 讨论抗纤维解药疗法,抗血管生成疗法和缺铁性贫血管理.
主要方法:
- 审查已发表的数据和临床经验.
- HHT出血呈现的案例研究插图.
- 讨论系统性疗法,包括抗纤维素催化剂和抗血管生成药.
主要成果:
- 抗纤维解药对轻度至中度的HHT出血是安全有效的.
- 系统性抗血管新生药物,如波马利多米德和贝瓦奇祖马布,对中度至重度出血有效.
- 转向系统医疗治疗而不是程序管理的转变得到了证据的支持.
结论:
- 现代基于证据的方法对于管理与HHT相关的出血至关重要.
- 系统性抗纤维解质和抗血管生成疗法代表了HHT治疗的范式转变.
- 在整个HHT疾病谱中,对缺铁性贫血的综合管理至关重要.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
58
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
58
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Introduction to Hemostasis
7.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.3K
Epistaxis
144
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
144
Disorders of Hemostasis
837
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
837
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157


